Atai Life Sciences N.V. (ATAI) |
1.97 0.1 (5.35%) 04-23 16:00 |
Open: | 1.87 |
High: | 2.07 |
Low: | 1.87 |
Volume: | 1,158,766 |
Market Cap: | 327(M) |
PE Ratio: | -7.88 |
Exchange: | NASDAQ Global Market |
Industry: | Biotechnology |
Sector: | Healthcare |
Technical analysis | ||||
sell | buy |
Resistance 2: | 2.85 |
Resistance 1: | 2.36 |
Pivot price: | 2.22 |
Support 1: | 1.58 |
Support 2: | 1.31 |
52w High: | 2.85 |
52w Low: | 1.025 |
Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.
EPS | -121950000.000 |
Book Value | 0.000 |
PEG Ratio | 0.00 |
Gross Profit | -53.673 |
Profit Margin (%) | 0.00 |
Operating Margin (%) | -186.00 |
Return on Assets (ttm) | 483.3 |
Return on Equity (ttm) | -25.5 |
Thu, 04 Apr 2024
Atai Life Sciences executive sells $114k in company stock - Investing.com
Thu, 04 Apr 2024
Atai Life Sciences CFO sells $50708 in company stock - Investing.com
Thu, 04 Apr 2024
Are You Looking for a Top Momentum Pick? Why atai Life Sciences N.V. (ATAI) is a Great Choice - Yahoo Finance
Wed, 03 Apr 2024
Atai Life Sciences stock upgraded at Maxim (NASDAQ:ATAI) - Seeking Alpha
Mon, 01 Apr 2024
Where Will ATAI Life Sciences NV (ATAI) Stock Go Next After It Is Up 12.88% in a Week? - InvestorsObserver
Thu, 28 Mar 2024
atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical ... - GlobeNewswire
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |